Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Flawed mothering or infant signaling? The effects of deficient acoustic cues on ovine maternal response.

Morton CL, Hinch G, Small A, McDonald PG.

Dev Psychobiol. 2018 Dec;60(8):975-988. doi: 10.1002/dev.21769. Epub 2018 Aug 10.

PMID:
30098006
2.

In-bag enzymatic splenic digestion: a novel alternative to manual morcellation?

Villarreal ED, Hewgley WP, Lang WH, Morton CL, Mao S, Wu J, Sandoval JA.

J Surg Res. 2017 Oct;218:209-216. doi: 10.1016/j.jss.2017.05.060. Epub 2017 Jun 21.

PMID:
28985851
3.

Distress vocalization delay in the neonate lamb as a neurobehavioral assessment tool.

Morton CL, Hinch G, Small A.

Dev Psychobiol. 2017 May;59(4):523-534. doi: 10.1002/dev.21517. Epub 2017 Apr 9.

PMID:
28391612
4.

Distribution of AAV8 particles in cell lysates and culture media changes with time and is dependent on the recombinant vector.

Piras BA, Drury JE, Morton CL, Spence Y, Lockey TD, Nathwani AC, Davidoff AM, Meagher MM.

Mol Ther Methods Clin Dev. 2016 Mar 30;3:16015. doi: 10.1038/mtm.2016.15. eCollection 2016.

5.

Regulated lysosomal exocytosis mediates cancer progression.

Machado E, White-Gilbertson S, van de Vlekkert D, Janke L, Moshiach S, Campos Y, Finkelstein D, Gomero E, Mosca R, Qiu X, Morton CL, Annunziata I, d'Azzo A.

Sci Adv. 2015 Dec 18;1(11):e1500603. doi: 10.1126/sciadv.1500603. eCollection 2015 Dec.

6.

The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.

Yang J, AlTahan AM, Hu D, Wang Y, Cheng PH, Morton CL, Qu C, Nathwani AC, Shohet JM, Fotsis T, Koster J, Versteeg R, Okada H, Harris AL, Davidoff AM.

J Natl Cancer Inst. 2015 Apr 29;107(6):djv080. doi: 10.1093/jnci/djv080. Print 2015 Jun.

7.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM.

N Engl J Med. 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309.

8.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.

Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R.

Pediatr Blood Cancer. 2014 Feb;61(2):245-52. doi: 10.1002/pbc.24724. Epub 2013 Sep 4.

9.

Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, Patel N, Tuddenham EG, Christophe OD, McVey JH, Waddington S, Nienhuis AW, Gray JT, Fagone P, Mingozzi F, Zhou SZ, High KA, Cancio M, Ng CY, Zhou J, Morton CL, Davidoff AM, Nathwani AC.

Blood. 2013 Apr 25;121(17):3335-44. doi: 10.1182/blood-2012-10-462200. Epub 2013 Feb 20.

10.

Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-κB activity.

Orr WS, Denbo JW, Saab KR, Ng CY, Wu J, Li K, Garner JM, Morton CL, Du Z, Pfeffer LM, Davidoff AM.

PLoS One. 2013;8(2):e51309. doi: 10.1371/journal.pone.0051309. Epub 2013 Feb 7.

11.

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.

Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 May;60(5):783-90. doi: 10.1002/pbc.24368. Epub 2013 Jan 17.

12.

Inhibition of type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-345541 and TPCA-1.

Du Z, Whitt MA, Baumann J, Garner JM, Morton CL, Davidoff AM, Pfeffer LM.

J Interferon Cytokine Res. 2012 Aug;32(8):368-77. doi: 10.1089/jir.2012.0002. Epub 2012 Apr 17. Erratum in: J Interferon Cytokine Res. 2016 Aug;36(8):525.

13.

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1266-74. doi: 10.1002/pbc.24073. Epub 2012 Feb 7.

14.

Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition.

Orr WS, Denbo JW, Saab KR, Myers AL, Ng CY, Zhou J, Morton CL, Pfeffer LM, Davidoff AM.

Surgery. 2012 May;151(5):736-44. doi: 10.1016/j.surg.2011.12.014. Epub 2012 Jan 28. Retraction in: Surgery. 2016 Feb;159(2):674.

15.

Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.

Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2012 Sep;59(3):586-8. doi: 10.1002/pbc.24016. Epub 2011 Dec 20.

16.

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM.

N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoa1108046. Epub 2011 Dec 10.

17.

AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage.

Binny C, McIntosh J, Della Peruta M, Kymalainen H, Tuddenham EG, Buckley SM, Waddington SN, McVey JH, Spence Y, Morton CL, Thrasher AJ, Gray JT, Castellino FJ, Tarantal AF, Davidoff AM, Nathwani AC.

Blood. 2012 Jan 26;119(4):957-66. doi: 10.1182/blood-2011-09-377630. Epub 2011 Dec 1.

18.

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ.

Pediatr Blood Cancer. 2012 Aug;59(2):246-53. doi: 10.1002/pbc.23357. Epub 2011 Oct 19. Erratum in: Pediatr Blood Cancer. 2012 Oct;59(4):772.

19.

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ.

Pediatr Blood Cancer. 2012 Aug;59(2):329-32. doi: 10.1002/pbc.23319. Epub 2011 Sep 15.

20.

Continuous local delivery of interferon-β stabilizes tumor vasculature in an orthotopic glioblastoma xenograft resection model.

Denbo JW, Williams RF, Orr WS, Sims TL, Ng CY, Zhou J, Spence Y, Morton CL, Nathwani AC, Duntsch C, Pfeffer LM, Davidoff AM.

Surgery. 2011 Sep;150(3):497-504. doi: 10.1016/j.surg.2011.07.044.

21.

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA.

Pediatr Blood Cancer. 2011 Sep;57(3):443-53. doi: 10.1002/pbc.22921. Epub 2010 Dec 27.

22.

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.

Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA.

Pediatr Blood Cancer. 2012 Apr;58(4):636-9. doi: 10.1002/pbc.23167. Epub 2011 Jun 16.

23.

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2012 May;58(5):729-35. doi: 10.1002/pbc.23157. Epub 2011 May 31.

24.

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.

Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2012 Jun;58(6):916-23. doi: 10.1002/pbc.23176. Epub 2011 May 16.

25.

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA.

Pediatr Blood Cancer. 2012 Feb;58(2):200-9. doi: 10.1002/pbc.23016. Epub 2011 May 5.

26.

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

Morton CL, Maris JM, Keir ST, Gorlick R, Kolb EA, Billups CA, Wu J, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2012 Apr;58(4):566-71. doi: 10.1002/pbc.23159. Epub 2011 Apr 29.

27.

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA.

Pediatr Blood Cancer. 2012 Jul 15;59(1):185-8. doi: 10.1002/pbc.23154. Epub 2011 Apr 29.

28.

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1291-304. doi: 10.1007/s00280-011-1618-8. Epub 2011 Mar 30.

29.

Initial testing of lenalidomide by the pediatric preclinical testing program.

Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2011 Oct;57(4):606-11. doi: 10.1002/pbc.22877. Epub 2011 Feb 25.

30.

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ.

Pediatr Blood Cancer. 2011 Aug;57(2):268-74. doi: 10.1002/pbc.22797. Epub 2011 Feb 25.

31.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.

Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA.

Pediatr Blood Cancer. 2012 Feb;58(2):191-9. doi: 10.1002/pbc.22935. Epub 2011 Feb 18.

32.

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2011 Apr;56(4):595-603. doi: 10.1002/pbc.22741. Epub 2010 Dec 22.

33.

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.

Houghton PJ, Morton CL, Kang M, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1224-6. doi: 10.1002/pbc.22355.

34.

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP.

Pediatr Blood Cancer. 2011 Feb;56(2):239-49. doi: 10.1002/pbc.22801. Epub 2010 Oct 4.

35.

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA.

Pediatr Blood Cancer. 2010 Oct;55(4):668-77. doi: 10.1002/pbc.22576.

36.

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB.

Pediatr Blood Cancer. 2010 Dec 15;55(7):1329-37. doi: 10.1002/pbc.22710. Epub 2010 Aug 25.

37.

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.

Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1126-33. doi: 10.1002/pbc.22712.

38.

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.

Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2010 Aug;55(2):295-303. doi: 10.1002/pbc.22535. Erratum in: Pediatr Blood Cancer. 2012 Apr;58(4):652.

39.

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA.

Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6. doi: 10.1002/pbc.22367.

40.

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2010 Jul 15;55(1):26-34. doi: 10.1002/pbc.22430.

41.

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.

Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA.

Mol Cancer Ther. 2010 Jan;9(1):101-12. doi: 10.1158/1535-7163.MCT-09-0952. Epub 2010 Jan 6.

42.

Initial testing of topotecan by the pediatric preclinical testing program.

Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Watkins A, Smith MA, Lock RB.

Pediatr Blood Cancer. 2010 May;54(5):707-15. doi: 10.1002/pbc.22352.

43.

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.

Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ.

Pediatr Blood Cancer. 2010 Feb;54(2):307-10. doi: 10.1002/pbc.22188.

44.

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ.

Cancer Res. 2009 Oct 1;69(19):7662-71. doi: 10.1158/0008-5472.CAN-09-1693. Epub 2009 Sep 29.

45.

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.

Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA.

Pediatr Blood Cancer. 2009 Oct;53(4):594-8. doi: 10.1002/pbc.21989.

46.

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.

Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63. doi: 10.1002/pbc.22056.

47.

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA.

Pediatr Blood Cancer. 2009 Sep;53(3):505-8. doi: 10.1002/pbc.21988.

48.

Initial testing of aplidin by the pediatric pre-clinical testing program.

Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA.

Pediatr Blood Cancer. 2009 Sep;53(3):509-12. doi: 10.1002/pbc.21976.

49.

Molecular characterization of the pediatric preclinical testing panel.

Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ.

Clin Cancer Res. 2008 Jul 15;14(14):4572-83. doi: 10.1158/1078-0432.CCR-07-5090.

50.

Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.

Keir ST, Morton CL, Billups C, Smith MA, Houghton PJ, Gururangan S.

Pediatr Blood Cancer. 2008 Sep;51(3):439-41. doi: 10.1002/pbc.21620.

Supplemental Content

Loading ...
Support Center